Viking Touts Promising Phase I Weight Loss Data for Obesity Pill Candidate
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy VK2735 exceeded expectations, with “class-leading” weight loss. Patients on 100-miligram doses of the pill lost 8.
Viking Therapeutics Inc.’s stock rose 2% Friday as excitement continued to build about data on its oral weight-loss drug the ...
Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...
People taking phentermine can lose over 7% of their body weight, or at least 8 pounds.
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
Fish oil pills slash the risk of a heart attack or stroke among patients at high risk, according to research. Scientists ...
Discover the best and safest weight loss supplements that support your healthy dieting and exercise routine. From fat burners ...
Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...
Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback